TEZSPIRE®
(tezepelumab-ekko) Subcutaneous Injection 210 mg

STARTING APPROPRIATE PATIENTS ON TEZSPIRE®

Your office. Your preference. Your path to TEZSPIRE for your patients.

This guide walks you through the fulfillment pathways so you can help your patients move from prescription to therapy. TEZSPIRE administration and fulfillment options mean you can choose to access TEZSPIRE in a way that works for your patients.

Questions? We're here to help.

Contact TEZSPIRE Together Monday-Friday, 8 AM–8 PM ET at **1-888-TZSPIRE (1-888-897-7473).**

INDICATIONS

TEZSPIRE is indicated for:

- the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus
- the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

Please see additional Important Safety Information on page 7.

CHOOSE A TEZSPIRE FULFILLMENT PATHWAY

	Pre-filled Pen	Pre-filled Syringe	
PRIMARY BENEFIT TYPE:	Pharmacy Benefit	Medical Benefit	
PATHWAY:	Specialty Pharmacy	White Bag* *(via Specialty Pharmacy)*	Buy and Bill/ASOC
HOW TO INITIATE BV/Rx:	*Send* eRx to ASPN Pharmacies† *or* Specialty Pharmacy via EMR/EHR *or* ASPN HCP Portal ASPN NPI: 1538590690 | NCPDP: 3147863		*Submit* TEZSPIRE Together Enrollment Form via TEZSPIRE Together HCP Portal *or* FAX

You can assist patients with enrolling via TEZSPIRETogetherHCP.com, by calling 1-888-TZSPIRE (1-888-897-7473), or faxing the printed enrollment form to 1-888-388-6016.

ASOC=alternate site of care; BV=benefits verification; EHR=electronic health record; EMR=electronic medical record; eRx=electronic prescription; HCP=healthcare professional; Rx=prescription.

*White-bagging means the Specialty Pharmacy sends the medication directly to the doctor's office, where the provider administers it to the patient. The office does not buy or store the medication themselves.

†Amgen has entered into a contract with ASPN Pharmacies to provide services to support appropriate patient access to TEZSPIRE® after the prescribing decision has been made.

TEZSPIRE® (tezepelumab-ekko) Subcutaneous Injection 210 mg

Pharmacy & Medical Benefit

SPECIALTY PHARMACY (INCLUDING WHITE BAG)

PRE-FILLED SYRINGE

PRE-FILLED PEN

Initiating BV/Rx:

Send eRx to ASPN Pharmacies *or* Specialty Pharmacy via EMR/EHR or ASPN HCP Portal

What happens next:

ASPN/Specialty Pharmacy completes benefits verification and provides outcome and PA requirements (if applicable) to HCP office

HCP Office submits required and/or missing information sent back from specialty pharmacy until PA outcome is determined

ASPN/Specialty Pharmacy facilitates co-pay program* enrollment for eligible commercially insured patients and assists with payment and shipment coordination

Remind patients to answer the phone: The specialty pharmacy will be calling the patient to confirm details and schedule delivery. Answering the call helps prevent delays in starting therapy.

*Eligibility criteria and program maximums apply. Visit TEZSPIRE.com for full Terms and Conditions.

TEZSPIRE® (tezepelumab-ekko) Subcutaneous injection 210 mg

Medical Benefit

BUY AND BILL

PRE-FILLED SYRINGE

Initiating BV/Rx:

Submit **TEZSPIRE Together Enrollment Form** via TEZSPIRE Together HCP Portal or *FAX*

What happens next:

TEZSPIRE® Together Hub can provide benefits verification outcome to HCP office and help with financial support options (including co-pay program enrollment)

HCP Office submits prior authorization via patient insurer portal or phone and, if denied, submits appeal

HCP Office informs patient about approval status, cost, and injection scheduling

HCP Office ensures all required steps above are completed before ordering the product (co-pay program enrollment for commercially insured patients, benefits verification, etc)

Questions? We're here to help.

Contact TEZSPIRE Together Monday-Friday, 8 AM-8 PM ET at **1-888-TZSPIRE (1-888-897-7473).**

TEZSPIRE® (tezepelumab-ekko) Subcutaneous Injection 210 mg

QUICK REFERENCE FOR PRIOR AUTHORIZATIONS

The information below is commonly required for TEZSPIRE PA submissions. Refer to the TEZSPIRE PA and Appeals Guide for more details.

Product Information

TEZSPIRE (tezepelumab-ekko) 210mg/1.91mL **Pre-filled Syringe: 55513-0112-0**	TEZSPIRE (tezepelumab-ekko) 210mg/1.91mL **Pre-filled Pen: 55513-0123-0**

Diagnosis codes (ICD-10-CM)*

SEVERE UNCONTROLLED ASTHMA (SUA)		CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP)	
J45.50 Severe persistent asthma, uncomplicated	**J45.51** Severe persistent asthma, with (acute) exacerbation	**J33.0** Polyp of nasal cavity	**J33.1** Polypoid sinus degeneration
J82.83 Eosinophilic asthma	**J45.5** Severe persistent asthma	**J33.8** Other polyp of sinus	**J33.9** Nasal polyp, unspecified

PA=Prior authorization.

*The ICD-10-CM diagnosis codes listed above are provided only as examples of potentially relevant codes. Providers should consult a current ICD-10-CM manual and always select the most appropriate diagnosis code(s) with the highest level of specificity to describe a patient's actual condition.

Click here to download the TEZSPIRE PA and Appeals Guide for more details

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Please see additional Important Safety Information on page 7.

TEZSPIRE® (tezepelumab-ekko) Subcutaneous Injection 210 mg

RESOURCES

If you're not sure where to start, TEZSPIRE Together is here to help. You can track prescriptions, prior authorizations, and benefit verifications in the TEZSPIRE Together HCP Portal or assist your patients with enrolling via phone or fax.

TEZSPIRE Together HCP Portal Designed to streamline submissions and reduce missing information **Website: TEZSPIRETogetherHCP.com**	**Phone:** 1-888-TZSPIRE (1-888-897-7473) **Fax:** 1-888-388-6016 **Hours of operation:** Monday-Friday, 8:00 AM to 8:00 PM ET
Field Reimbursement Managers (FRMs) Provide access education and support	FRMs provide access education and assist with specific cases. Connect with your FRM directly or by calling TEZSPIRE Together at 1-888-TZSPIRE (1-888-897-7473).
ASPN Pharmacies **Website: ASPNPharmacies.com** **NPI: 1538590690**	**ASPN Pharmacies, LLC** 290 West Mount Pleasant Ave, Livingston, NJ 07039 **Phone:** (866) 910-0088 **Fax:** (866) 829-9311 **Hours of operation:** Monday-Friday, 8:30 AM to 8:00 PM ET

TEZSPIRE®
(tezepelumab-ekko) Subcutaneous Injection 210 mg

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 3%) are:

- **Asthma:** pharyngitis, arthralgia, and back pain.
- **Chronic rhinosinusitis with nasal polyps:** nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

Please see full Prescribing Information, including Patient Information and Instructions for Use.

You may **report side effects related to AstraZeneca products.**

TEZSPIRE® (tezepelumab-ekko) Subcutaneous Injection 210 mg

NOTES:

Questions? We're here to help.

Contact TEZSPIRE Together Monday–Friday, 8 AM–8 PM ET at **1-888-TZSPIRE (1-888-897-7473).**

Name: _____

Email: _____

Phone: _____

TEZSPIRE® (tezepelumab-ekko) Subcutaneous Injection 210 mg

TEZSPIRE®
(tezepelumab-ekko) Subcutaneous Injection 210 mg

TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
©2025 Amgen Inc. All rights reserved. US-104631 | USA-157-81636 10/25

AMGEN AstraZeneca